clinical trial · NCT07603401
Expanded Access Program of Bitopertin For Participants With EPP or XLP
Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)DISC-1459
brief summary
The goal of this expanded access program is to provide bitopertin to patients with EPP and XLP who have no satisfactory treatment options available in the US and to learn if bitopertin is safe to treat EPP and XLP.
started
—
primary completion
—
completion
—
last updated
Jun 30, 2026
official title
Expanded Access Program Protocol: Bitopertin (DISC-1459) For The Treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol